Stock ASMB ASSEMBLY BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Assembly Biosciences, Inc.

Equities

ASMB

US0453962070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
12.65 USD -5.31% Intraday chart for Assembly Biosciences, Inc. -5.67% +28.54%
Mar. 28 Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 19 Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing MT

Evolution of the average Target Price on Assembly Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3b5b.o1nD748QKOY0qpryXoTWDOfm1S4XZ0s5Vzipd8NCJxI.8QH3mrZqerIExsrKPdymf4al7Gt5DwV-Emf9FPodQnaTH4um5n5uiVfcrg~f7e36b0234e7dd59a74a52dde613614f

Analyst Recommendations on Assembly Biosciences, Inc.

HC Wainwright Adjusts Price Target on Assembly Biosciences to $1.50 From $2.50, Keeps Neutral Rating MT
Mizuho Cuts Price Target on Assembly Biosciences to $3 From $14, Keeps Buy Rating MT
Truist Securities Downgrades Assembly Biosciences to Hold From Buy, Adjusts Price Target to $2 From $11 MT
HC Wainwright Adjusts Assembly Biosciences Price Target to $2.50 From $3,50, Maintains Buy Rating MT
Truist Securities Adjusts Assembly Biosciences Price Target to $12 From $15, Maintains Buy Rating MT
ASSEMBLY BIOSCIENCES : HC Wainwright Starts Assembly Biosciences at Neutral with $3.50 Price Target MT
ASSEMBLY BIOSCIENCES : William Blair Downgrades Assembly Biosciences to Market Perform From Outperform MT
ASSEMBLY BIOSCIENCES : Mizuho Securities Adjusts Price Target on Assembly Biosciences to $14 From $13 on Lower Expenses, Reiterates Buy Rating MT
ASSEMBLY BIOSCIENCES : SVB Leerink Adjusts Price Target for Assembly Biosciences to $7 From $8, Maintains Market Perform Rating MT
ASSEMBLY BIOSCIENCES : SVB Leerink Downgrades Assembly Biosciences to Market Perform From Outperform, Adjusts PT to $8 From $9 MT
ASSEMBLY BIOSCIENCES : Jefferies Adjusts Price Target for Assembly Biosciences to $7 From $10, Maintains Hold Rating MT
ASSEMBLY BIOSCIENCES : Mizuho Adjusts Assembly Biosciences' PT to $13 From $30 After H0731 'Failure in Finite Therapy;' Buy Rating Kept on Undervalued Chronic Suppressive Therapy MT
ASSEMBLY BIOSCIENCES : Jefferies Downgrades Assembly Biosciences to Hold From Buy; Price Target is $10 MT
Assembly Biosciences, Inc. Announces Results from Research Study Evaluating the Turnover Rate of Covalently Closed Circular DNA, Which Plays Pivotal Role in the Establishment and Persistence of HBV Infection CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
12.65 USD
Average target price
36 USD
Spread / Average Target
+184.58%
High Price Target
36 USD
Spread / Highest target
+184.58%
Low Price Target
36 USD
Spread / Lowest Target
+184.58%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Assembly Biosciences, Inc.

HC Wainwright
Mizuho Securities
Truist Securities
William Blair & Co.
SVB Leerink

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ASMB Stock
  4. Consensus Assembly Biosciences, Inc.